Literature DB >> 33528730

Development and application of reverse genetic technology for the influenza virus.

Ziquan Li1, Liping Zhong1, Jian He1, Yong Huang1, Yongxiang Zhao2.   

Abstract

Influenza virus is a common virus in people's daily lives, and it has certain infectivity in humans and animals. Influenza viruses have the characteristics of a high mutation rate and wide distribution. Reverse genetic technology is primarily used to modify viruses at the DNA level through targeted modification of the virus cDNA. Genetically modified influenza viruses have a unique advantage when researching the transmission and pathogenicity of influenza. With the continuous development of oncolytic viruses in recent years, studies have found that influenza viruses also have certain oncolytic activity. Influenza viruses can specifically recognize tumor cells; activate cytotoxic T cells, NK cells, dendritic cells, etc.; and stimulate the body to produce an immune response, thereby killing tumor cells. This article will review the development and application of influenza virus reverse genetic technology.

Entities:  

Keywords:  Antitumor; Influenza virus; Reverse genetic technology; Vaccine

Year:  2021        PMID: 33528730      PMCID: PMC7851324          DOI: 10.1007/s11262-020-01822-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  106 in total

1.  Construction of hybrid viruses containing SV40 and lambda phage DNA segments and their propagation in cultured monkey cells.

Authors:  S P Goff; P Berg
Journal:  Cell       Date:  1976-12       Impact factor: 41.582

2.  [Some pathogenetic characteristics of influenza infection in white mice].

Authors:  O G P'iankova; L E Bulychev; A N Sergeev; V A Petrishchenko; O V P'iankov; V A Zhukov; A B Ryzhikov; N G Kolesnikova; N K Evtin; L N Shishkina
Journal:  Vopr Virusol       Date:  1997 Sep-Oct

3.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.

Authors:  Yao Yu; Hai-Juan Qin; Xiao-Xiao Shi; Jia-Qi Song; Jia-Ping Zhou; Peng Yu; Zhen-Chuan Fan; Ming Zhong; Yang Yang
Journal:  Eur J Med Chem       Date:  2020-04-28       Impact factor: 6.514

5.  Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Authors:  Uzoma K Iheagwara; Pamela L Beatty; Phu T Van; Ted M Ross; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2013-12-05       Impact factor: 11.151

Review 6.  A Brief Introduction to Avian Influenza Virus.

Authors:  Erica Spackman
Journal:  Methods Mol Biol       Date:  2020

7.  Potential Pandemic of H7N9 Avian Influenza A Virus in Human.

Authors:  Zhiqing Pu; Dan Xiang; Xiaobing Li; Tingting Luo; Xuejuan Shen; Robert W Murphy; Ming Liao; Yongyi Shen
Journal:  Front Cell Infect Microbiol       Date:  2018-11-23       Impact factor: 5.293

8.  A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus.

Authors:  D Garcin; T Pelet; P Calain; L Roux; J Curran; D Kolakofsky
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

Review 9.  Structural Biology of Influenza Hemagglutinin: An Amaranthine Adventure.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Viruses       Date:  2020-09-22       Impact factor: 5.048

View more
  2 in total

Review 1.  Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.

Authors:  Chao Tang; Lan Li; Tong Mo; Jintong Na; Zhangbo Qian; Dianfa Fan; Xinjun Sun; Min Yao; Lina Pan; Yong Huang; Liping Zhong
Journal:  Clin Transl Oncol       Date:  2022-05-25       Impact factor: 3.340

2.  Evolution of Swine Influenza Virus H3N2 in Vaccinated and Nonvaccinated Pigs after Previous Natural H1N1 Infection.

Authors:  Álvaro López-Valiñas; Laura Baioni; Lorena Córdoba; Ayub Darji; Chiara Chiapponi; Joaquim Segalés; Llilianne Ganges; José I Núñez
Journal:  Viruses       Date:  2022-09-10       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.